Evidence map›Paper›PMID 33883598›Full record

ArticleScientific reports2021

Mechanistic and therapeutic distinctions between cardiosphere-derived cell and mesenchymal stem cell extracellular vesicle non-coding RNA.

Ann-Sophie Walravens, Sasha Smolgovsky, Liang Li, Lauren Kelly, Travis Antes, Kiel Peck, Tanner Quon, Ahmed Ibrahim, Eduardo Marbán, Benjamin Berman and 3 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Ann-Sophie WalravensCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA.
Sasha SmolgovskyCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA.
Liang LiCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA.
Lauren KellyCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA.
Travis AntesCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA.
Kiel PeckCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA.
Tanner QuonCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA.
Ahmed IbrahimSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Eduardo MarbánSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Benjamin BermanCenter for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Linda MarbánCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA. lmarban@capricor.com.
Luis R-BorladoCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA.
Geoffrey de CoutoCapricor Therapeutics, Inc., 8840 Wilshire Blvd., Beverly Hills, CA, 90211, USA. Geoffrey.decouto@cshs.org.
Capricor Therapeutics (United States) · USCedars-Sinai Smidt Heart Institute · USCedars-Sinai Medical Center · US

Funding

Exosome-mediated cardioprotection and regenerationR01HL124074 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MARBAN, EDUARDO · 2014 to 2021
$4.0M
NHLBI NIH HHS R01 HL124074
6 · The paper itself

Abstract

Cell therapy limits ischemic injury following myocardial infarction (MI) by preventing cell death, modulating the immune response, and promoting tissue regeneration. The therapeutic efficacy of cardiosphere-derived cells (CDCs) and mesenchymal stem cells (MSCs) is associated with extracellular vesicle (EV) release. Prior head-to-head comparisons have shown CDCs to be more effective than MSCs in MI models. Despite differences in cell origin, it is unclear why EVs from different adult stem cell populations elicit differences in therapeutic efficacy. Here, we compare EVs derived from multiple human MSC and CDC donors using diverse in vitro and in vivo assays. EV membrane protein and non-coding RNA composition are highly specific to the parent cell type; for example, miR-10b is enriched in MSC-EVs relative to CDC-EVs, while Y RNA fragments follow the opposite pattern. CDC-EVs enhance the Arg1/Nos2 ratio in macrophages in vitro and reduce MI size more than MSC-EVs and suppress inflammation during acute peritonitis in vivo. Thus, CDC-EVs are distinct from MSC-EVs, confer immunomodulation, and protect the host against ischemic myocardial injury and acute inflammation.

Indexed as

Mesenchymal Stem Cell TransplantationAdultAnimalsChildChild, PreschoolDisease Models, AnimalExtracellular VesiclesFemaleHumansMaleMesenchymal Stem CellsMiceMice, Inbred C57BLMice, SCIDMiddle AgedMyocardial InfarctionRNA, Untranslated

Identifiers

PMID33883598
PMCPMC8060398
OpenAlexW3156552319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.